ArticleBiosensors2026
A High Sensitivity and Anti-Scaling Surface Plasmon Resonance Sensor for Early Screening of Colorectal Cancer.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Early screening is essential for improving the prognosis of colorectal cancer (CRC), for which fecal occult blood testing (FOBT) remains one of the most widely adopted noninvasive screening approaches. However, conventional FOBT methods often exhibit insufficient sensitivity and limited reliability when handling complex fecal matrices, largely due to nonspecific fouling and cumbersome sample pretreatment procedures. Herein, we report a surface plasmon resonance biosensor integrating a self-assembled anti-fouling interface with DNA aptamer-mediated molecular recognition for sensitive hemoglobin detection in fecal samples. The engineered sensing surface exhibits high interfacial stability and resistance to nonspecific adsorption, enabling direct analysis of fecal samples without complicated pretreatment. The proposed platform achieved a detection limit of 1 nM and a diagnostic accuracy of 97.6%. This study demonstrates the feasibility of SPR-based hemoglobin detection in complex fecal samples using an antifouling sensing interface and highlights its potential as a promising optical biosensing strategy for noninvasive colorectal cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.